rana mckay, md, on the real world impact of immunotherapy when added to oral therapies for apc
Published 4 years ago • 169 plays • Length 1:04
Download video MP4
Download video MP3
Similar videos
-
1:22
anis hamid, md, describes real world impact of immunotherapy when added to oral therapies for apc
-
5:30
dr. rana mckay on frontline immunotherapy for metastatic rcc
-
1:23
rana mckay, md, explains how to differentiate between tkis available for renal cell cancer patients
-
1:59
meet rana r. mckay, md: medical oncologist
-
1:23
rana mckay, md, on recent data examining atezolizumab and bevacizumab in nccrcc & sccrcc
-
2:37
rana mckay md, explains approach to treating 2nd-line rcc patients who have received i-o combination
-
1:39
rana mckay, md, deliberates on patient types appropriate to receive a tki in the treatment of rcc
-
0:53
rana mckay, md, shares exciting potential of current late-stage clinical studies in rcc patients
-
0:44
rana mckay, md, elaborates on the outcomes of the keynote 426 phase iii study in mrcc
-
4:03
rana mckay, md, elaborates on the advent of hormonal agents for patients with mpc
-
1:01
rana mckay, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
1:01
rana mckay, md, discusses checkmate214 investigating nivolumab ipilimumab in 1st line rcc patients
-
1:21
rana mckay, md, considers the implications of checkmate 214 & keynote-426 presented at gu 2019
-
1:14
immunotherapy at penn: a history
-
42:53
biomarkers in cancer immunotherapy: how much do they matter?
-
5:13
the role of immunotherapy in treating r/r mhcc
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
0:59
dr. mckay discusses immunotherapy trials in rcc
-
1:21
immunotherapy and targeted treatment for mnsclc | neal ready, md, phd | esmo22 pennsylvania
Clip.africa.com - Privacy-policy